Sotorasiib Dosage and Dosage: How to Take This Medication Correctly

Sotorasib (AMG510, Sotorasib) is the first KRAS G12C inhibitor approved by the FDA. It is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, provided that the patient has received at least one systemic treatment. The emergence of this drug breaks through the problem that KRAS mutations have long been considered "undruggable" and provides patients with a new targeted treatment option. Correct administration and dosage are critical when using sotoraxib to ensure maximum efficacy and minimize side effects.

The standard dose of sotoraxib is960mg, taken orally once daily, and it is recommended to take it at the same time every day. The drug should be swallowed whole and should not be crushed, chewed or broken to avoid affecting the drug release mechanism. Sotorasiib can be taken with or without food, but it is best to follow your doctor's recommendations to optimize drug absorption and reduce gastrointestinal discomfort.

If you miss a dose and it is more than 6 hours before the next dose, you should take it as soon as possible. If the time is less than 6 hours, skip this dose and wait for the next dose. Do not double the dose to compensate for the missed dose to avoid increasing the risk of side effects.

Common adverse reactions while taking sotoraxib include diarrhea, nausea, vomiting, fatigue, and elevated liver enzymes. Most patients' adverse reactions are mild to moderate and can be alleviated by adjusting lifestyle or symptomatic treatment. If serious side effects occur, such as persistent diarrhea or abnormal liver function, you should contact your doctor promptly and adjust the dose or suspend treatment if necessary.

For patients who cannot tolerate the adverse reactions, doctors may consider reducing the dose to 480 mg once daily or further reducing it to 240 mg once daily. However, if the 240 mg dose is still not tolerated, the drug may need to be discontinued. Sotorasiib is not recommended for use in patients with severe hepatic impairment due to its dependence on the liver for metabolism.

Reference materials:https://www.lumakras.com/